[go: up one dir, main page]

WO2017201200A8 - Therapeutic compositions containing rar-alpha antagonists - Google Patents

Therapeutic compositions containing rar-alpha antagonists Download PDF

Info

Publication number
WO2017201200A8
WO2017201200A8 PCT/US2017/033172 US2017033172W WO2017201200A8 WO 2017201200 A8 WO2017201200 A8 WO 2017201200A8 US 2017033172 W US2017033172 W US 2017033172W WO 2017201200 A8 WO2017201200 A8 WO 2017201200A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
therapeutic compositions
alpha antagonists
rar
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/033172
Other languages
French (fr)
Other versions
WO2017201200A1 (en
Inventor
Scott Mcnear THACHER
Paul Damian CROWE
Haiyan TAO
Raj Kumar Raheja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orphagen Pharmaceuticals Inc
Original Assignee
Orphagen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphagen Pharmaceuticals Inc filed Critical Orphagen Pharmaceuticals Inc
Publication of WO2017201200A1 publication Critical patent/WO2017201200A1/en
Publication of WO2017201200A8 publication Critical patent/WO2017201200A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are methods associated with the use of selective retinoic acid receptor (RAR) antagonists, such as RARα-selective antagonists, for single-agent therapy or combination cancer, tumor or tumor metastases therapy
PCT/US2017/033172 2016-05-19 2017-05-17 Therapeutic compositions containing rar-alpha antagonists Ceased WO2017201200A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338883P 2016-05-19 2016-05-19
US62/338,883 2016-05-19

Publications (2)

Publication Number Publication Date
WO2017201200A1 WO2017201200A1 (en) 2017-11-23
WO2017201200A8 true WO2017201200A8 (en) 2017-12-28

Family

ID=60325598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/033172 Ceased WO2017201200A1 (en) 2016-05-19 2017-05-17 Therapeutic compositions containing rar-alpha antagonists

Country Status (1)

Country Link
WO (1) WO2017201200A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214575A1 (en) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2019014492A1 (en) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
KR20200044889A (en) 2017-08-31 2020-04-29 아이오 테라퓨틱스, 인크. RAR selective agonists in combination with immunomodulators for cancer immunotherapy
CN115335367B (en) * 2019-12-19 2024-08-13 奥弗恩制药公司 RAR-alpha compounds for inflammatory diseases and male contraception
US12115140B2 (en) 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200316T3 (en) * 1997-03-11 2004-03-01 Les Laboratoires Aeterna Inc. COMPOSITIONS TO TREAT TUMORS CONTAINING EXTRACTS OF SHARK CARTILAGO AND ANTINEOPLASTIC AGENTS.
ES2702128T3 (en) * 2006-05-16 2019-02-27 Io Therapeutics Llc Antagonist or reverse RAR agonist for use in the treatment of side effects of chemotherapy and / or radiation therapy

Also Published As

Publication number Publication date
WO2017201200A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (en) Modulatory polynucleotides.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
NZ737399A (en) Ccr2 modulators
WO2016011222A3 (en) Circular polynucleotides
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
PL3224254T3 (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
WO2015192127A3 (en) Formulated receptor polypeptides and related methods
MX363347B (en) Salt of omecamtiv mecarbil and process for preparing salt.
WO2015118342A8 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
CL2015000337A1 (en) Compounds derived from substituted 2,3-benzodiazepines; intermediary compounds; pharmaceutical formulation; use for the prophylaxis and / or therapy of tumor disorders such as leukemia, prostate carcinoma, breast carcinoma, melanomas, among others and male fertility control.
MX2020010674A (en) Muscarinic receptor agonists.
EP3273994A4 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2022001310A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds.
WO2017201200A8 (en) Therapeutic compositions containing rar-alpha antagonists
EA033197B1 (en) SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GluN2B RECEPTOR MODULATORS
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2014152809A3 (en) Analogs of pparo and 20-oh-pge2, and methods of using the same
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17800116

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17800116

Country of ref document: EP

Kind code of ref document: A1